Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History NVCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics NVCR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Novocure Ltd

NVCR
Current price
17.42 USD -0.03 USD (-0.17%)
Last closed 17.60 USD
ISIN JE00BYSS4X48
Sector Healthcare
Industry Medical Devices
Exchange NASDAQ
Capitalization 2 088 564 352 USD
Yield for 12 month -3.17 %
1Y
3Y
5Y
10Y
15Y
NVCR
21.11.2021 - 28.11.2021

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. Address: Neuhofstrasse 21, Baar, Switzerland, 6340

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

32.57 USD

P/E Ratio

Dividend Yield

Financials NVCR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures NVCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+605 220 000 USD

Last Year

+509 338 000 USD

Current Quarter

+154 994 000 USD

Last Quarter

+161 266 000 USD

Current Year

+468 039 000 USD

Last Year

+381 058 000 USD

Current Quarter

+116 473 000 USD

Last Quarter

+127 800 000 USD
EBITDA -153 508 000 USD
Operating Margin TTM -24.43 %
Price to Earnings
Return On Assets TTM -8.64 %
PEG Ratio -0.47
Return On Equity TTM -45.52 %
Wall Street Target Price 32.57 USD
Revenue TTM 621 710 976 USD
Book Value 3.25 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 11.90 %
Dividend Yield
Gross Profit TTM 480 704 000 USD
Earnings per share -1.51 USD
Diluted Eps TTM -1.51 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -6.00 %
Profit Margin -26.41 %

Stock Valuation NVCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 909.09
Enterprise Value Revenue 2.89
Price Sales TTM 3.36
Enterprise Value EBITDA -6.92
Price Book MRQ 5.60

Technical Indicators NVCR

For 52 Weeks

14.17 USD 34.13 USD
50 Day MA 17.70 USD
Shares Short Prior Month 4 944 866
200 Day MA 20.18 USD
Short Ratio 3.33
Shares Short 5 228 810
Short Percent 7.02 %